Actavis Inc  

(Public, NYSE:ACT)   Watch this stock  
Find more results for NYSE:WPI
125.67
+0.73 (0.58%)
Jun 18 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 124.44 - 126.27
52 week 68.57 - 133.00
Open 125.22
Vol / Avg. 0.00/2.06M
Mkt cap 16.05B
P/E     -
Div/yield     -
EPS -0.47
Shares 127.75M
Beta 0.38
Inst. own 88%
Jul 22, 2013
Q2 2013 Actavis Inc Earnings Release Add to calendar
Jun 12, 2013
Actavis Inc at Goldman Sachs Healthcare Conference - Webcast
May 30, 2013
Actavis Inc at Sanford C Bernstein Strategic Decisions Conference - Webcast
May 20, 2013
Actavis to Acquire Warner Chilcott - Conference Call - Webcast
May 10, 2013
Actavis Inc Annual Shareholder Meeting
May 2, 2013
Q1 2013 Actavis Inc Earnings Conference Call - Webcast
May 2, 2013
Q1 2013 Actavis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -5.46% 1.66%
Operating margin -2.23% 5.42%
EBITD margin - 24.07%
Return on average assets -2.94% 0.95%
Return on average equity -11.09% 2.63%
Employees 17,700 -
Carbon Disclosure Rating - 83/100

Address

Morris Corporate Center III 400 Interpace Parkway
PARSIPPANY, NJ 07054
United States - Map
+1-862-2617000 (Phone)
+1-951-2701096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Actavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Officers and directors

Andrew L. Turner Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Paul M. Bisaro President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Sigurdur Oli Olafsson President - Actavis Pharma
Age: 44
Bio & Compensation  - Reuters
Robert A. Stewart President - Global Operations
Age: 45
Bio & Compensation  - Reuters
G. Frederick Wilkinson President - Actavis Specialty Brands
Age: 56
Bio & Compensation  - Reuters
David A. Buchen Chief Legal Officer, Global
Age: 48
Bio & Compensation  - Reuters
Patrick J. Eagan Chief Human Resource Officer, Global
Age: 55
Bio & Compensation  - Reuters
R. Todd Joyce CPA Chief Financial Officer, Global
Age: 55
Bio & Compensation  - Reuters
Charles M. Mayr Chief Communication Officer, Global
Age: 56
Bio & Compensation  - Reuters
Christopher W. Bodine Independent Director
Age: 57
Bio & Compensation  - Reuters